RxDoctor Payments Data

Riley Sibley, MD

Ophthalmology · Metairie, LANPI 1437129913

Payments from drug & device makers

$765in general payments, 2019–2025

Across 35 payments — averaging $21.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$178
  • Mallinckrodt Hospital Products Inc.$125
  • Bausch & Lomb Americas Inc.$59
  • Sun Pharmaceutical Industries Inc.$57
  • Dompe US, Inc.$48
  • Alcon$46
  • plus $252 from 10 others

What the payments were for

  • Food & beverage$765100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$765 in reported general payments places this provider in the 30th percentile of 286 ophthalmology providers in Louisiana.

See all ophthalmology providers in Louisiana

Medicare billing

Part B allowed, 2024
$64,106
Medicare patients
350
Services billed
716

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine23$15,655
CombiganBrimonidine Tartrate/Timolol33$9,551
Tobramycin-DexamethasoneTobramycin/Dexamethasone108$5,569
Alphagan PBrimonidine Tartrate13$5,537
LumiganBimatoprost13$4,996
Travoprost15$1,844
Latanoprost180$1,743
Prednisolone Acetate39$1,314
Timolol Maleate55$1,292
Brimonidine Tartrate32$328
Dorzolamide Hcl22$264
Ofloxacin19$225
ErythromycinErythromycin Base16$186
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat12$142
Doxycycline Hyclate23$142

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Combigan, Alphagan P, Lumigan$178$35,74082 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 286 ophthalmology providers in Louisiana.

Other ophthalmology in Metairie

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →